Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16641175 | 0.88 | CA2 (0.54) | CA2CA12CA1CA7CA9 | |
| SCHEMBL8866413 | 0.83 | AR (0.44) | ACHEARCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL8865717 | 0.83 | FFAR1 (0.41) | CA2CA12CA1CA7CA9 | |
| SCHEMBL18315294 | 0.81 | CA2 (0.52) | CA2CA12CA1CA7CA9 | |
| SCHEMBL8863260 | 0.81 | LMNA (0.40) | CYP1A2ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL8078442 | 0.81 | ALDH1A1 (0.47) | CYP1A2CYP2C19ALDH1A1POLBMAPK1 | |
| SCHEMBL8865914 | 0.81 | ACACB (0.46) | TSHRCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL8865572 | 0.81 | ALDH1A1 (0.44) | ACHEARCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30833875 | 0.81 | MAPT (0.42) | CYP1A2ALDH1A1POLBCYP1A1CYP1B1 | |
| SCHEMBL8863967 | 0.81 | RAB9A (0.46) | CYP1A2ALDH1A1MAPK1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4200298-B1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115867549-A | 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-27 | — | — | US | disclosed |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-26 | — | — | US | disclosed |
| US-10544143-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | CA2 4002/4885CA12 4688/4885CA1 4449/4885 |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | CA2 4002/4885CA12 4688/4885CA1 4449/4885 |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | CA2 1040/4885CA12 3758/4885CA1 3950/4885 |
| US-10544143-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | CA2 4002/4885CA12 4688/4885CA1 4449/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | CA2 1991/4885CA12 1807/4885CA1 3120/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | CA2 1877/4885CA12 875/4885CA1 1456/4885 |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | CA2 434/4885CA12 3431/4885CA1 2487/4885 |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | CA2 4002/4885CA12 4688/4885CA1 4449/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | CA2 1877/4885CA12 875/4885CA1 1456/4885 |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CA2 1485/4885CA12 3330/4885CA1 3989/4885 |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | CA2 4002/4885CA12 4688/4885CA1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.